医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

UL Convenes India Workplace Safety Council to Tackle Workplace Health and Safety Challenges in India

2016年05月26日 PM11:00
このエントリーをはてなブックマークに追加


 

CHICAGO

With the second highest number of deaths and injuries in the world resulting from workplace related accidents and illnesses, safety is a rising concern for leading organizations in India. Without a solution, the number of workplace safety incidents will continue rising as the country’s workforce is projected to expand by 8 to 9 million people annually for the next five years, according to International Labour Organization estimates.

To address this growing problem, UL’s Integrated Health and Safety Institute (IHSI), in partnership with UL’s Public Safety Office in India, held the first annual India Workplace Safety Council meeting in New Delhi on April 7, 2016. The Council aims to identify and develop solutions to key obstacles employers face in improving workplace safety and health.

UL’s IHSI is conducting research, developing effective training material and assisting in the creation and implementation of better standards for workplace health and safety. Key works from IHSI, including the Standard for Integrating Health and Safety in the Workplace and the Integrated Health and Safety Index, help organizations make informed decisions to enhance safety in workplaces and reduce the number of safety and health incidents.

“Workplace safety is an escalating concern for many leading organizations in India, not only out of a sense of empathy arising from disabilities and loss of life, but due to the staggering cost to the Indian economy,” said Todd Hohn, IHSI’s global director. “The country suffers a loss of at least 4 percent of its annual GDP to workplace related accidents and injuries.”

The first Council meeting was comprised of heads of corporate health and safety representing leading industry sectors such as pharmaceuticals, petroleum, power, and construction, along with leading representatives from the government of India.

The experts conceded that many companies fail to recognize the full economic impact of their lapses in safety, resulting in few changes to improve workplace safety regulations and little effort to determine the primary causes of workplace incidents. There is greater need for proactive research to help organizations make informed decisions to enhance safety in the workplace.

“As an organization dedicated to public safety, UL strives to bring our knowledge of best practices from around the world to the Council to ensure we all learn from mistakes that others have made and not repeat them ourselves,” said Hohn.

About UL’s Integrated Health and Safety Institute

Founded in June 2015, UL’s Integrated Health and Safety Institute (IHSI) is the first private sector not-for-profit institute dedicated to advancing the integration of workplace health and safety programs. IHSI provides world-class research, guidance, standards, and education to assist employers in integrating their health, safety and worker well-being initiatives. For more information, visit http://www.ulehssustainability.com/ihsi.

About UL

UL is a premier global independent safety science company that has championed progress for more than 120 years. Its nearly 11,000 professionals are guided by the UL mission to promote safe working and living environments for all people via two distinct entities: Underwriters Laboratories Inc., a 501(c)3 public charity, and UL LLC. UL uses research and standards to continually advance and meet ever-evolving safety needs. We partner with businesses, manufacturers, trade associations and international regulatory authorities to bring solutions to a more complex global supply chain. For more information, visit http://www.UL.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160526005804/en/

CONTACT

Arketi Group
Jo Morsberger, 404-929-0091, ext. 211
jmorsberger@arketi.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • 武田薬品がALK陽性非小細胞肺がんでのALUNBRIGTM(ブリガチニブ)のピボタル第2相ALTA試験の最新データを発表
  • Shinkowa Pharmaceutical Co., Ltd., Distributor of the World’s First Supplements Containing β-Nicotinamide Mononucleotide (NMN), Has Begun World-Wide Distribution of the Special Products “NMN PURE 3000″ and “NMN PURE 1500″
  • Interim Analysis of Ignyta’s Entrectinib Suggests Potential Best-in-Class Profile as a First-Line Targeted Therapy in Patients With ROS1-Positive Non-Small Cell Lung Cancer
  • Spectrum Pharmaceuticals Highlights Poziotinib Data in Non-Small-Cell Lung Cancer (NSCLC) Presented at the 18th IASLC World Conference on Lung Cancer in Japan
  • 武田呈报ALUNBRIGTM (brigatinib)治疗ALK阳性非小细胞肺癌枢纽性2期ALTA试验的更新结果